Carmelo Rizzari

List of Publications by Year
in descending order

148 papers	6,259 citations	81743 39 h-index	76769 74 g-index

148 all docs	148 docs citations	148 times ranked	6889 citing authors

#	Article	IF	Citations
1	Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study. Pediatric Blood and Cancer, 2022, 69, e29341.	0.8	5
2	Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leukemia. Haematologica, 2022, 107, 49-57.	1.7	26
3	Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione) Tj ETQq1 1 0.784314 rgBT /Overlo	1.7	34
4	Mucopolysaccharidosis-Plus Syndrome, a Rapidly Progressive Disease: Favorable Impact of a Very Prolonged Steroid Treatment on the Clinical Course in a Child. Genes, 2022, 13, 442.	1.0	8
5	NUP214â€“ABL1 fusion in childhood Tâ€ALL. Pediatric Blood and Cancer, 2022, 69, e29643.	0.8	4
6	Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 187-198.	0.6	2
7	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia, 2022, 36, 1516-1524.	3.3	21
8	Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEGâ€•<scp>l</scp> â€asparaginase product. Pediatric Blood and Cancer, 2022, , e29753.	0.8	2
9	FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD). Cancers, 2022, 14, 2475.	1.7	3
10	Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 289-300.	0.6	6
11	Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 325, 843.	3.8	166
12	Recommendations by the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) Working Group on preparedness of clinical trials about paediatric medicines process. Archives of Disease in Childhood, 2021, 106, 1149-1154.	1.0	4
13	Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants. Blood, 2021, 137, 1980-1984.	0.6	12
14	<scp>CD56</scp>, <scp>HLAâ€DR,</scp> and <scp>CD45</scp> recognize a subtype of childhood <scp>AML</scp> harboring <scp>CBFA2T3â€GLIS2</scp> fusion transcript. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 844-850.	1.1	10
15	Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?. Pediatric Blood and Cancer, 2021, 68, e29169.	0.8	18
16	Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients â€" a 25â€year Italian experience. British Journal of Haematology, 2021, 195, 278-283.	1.2	4
17	A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood Advances, 2021, 5, 2925-2934.	2.5	12
18	ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment. Blood Advances, 2021, 5, 5164-5178.	2.5	14

#	Article	IF	Citations
19	Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis. Blood, 2021, 138, 516-516.	0.6	4
20	Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia, 2020, 34, 1694-1700.	3.3	24
21	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. European Journal of Cancer, 2020, 141, 82-91.	1.3	15
22	High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapyâ€related Acute Myeloid Leukemia: Description of the First Pediatric Case. HemaSphere, 2020, 4, e471.	1.2	3
23	Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion. ESMO Open, 2020, 5, e000977.	2.0	23
24	Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study. Therapeutic Drug Monitoring, 2020, 42, 435-444.	1.0	11
25	Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. New England Journal of Medicine, 2020, 382, 1811-1822.	13.9	320
26	Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. European Journal of Cancer, 2020, 132, 11-16.	1.3	155
27	Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati. Bone Marrow Transplantation, 2020, 55, 1900-1905.	1.3	104
28	Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosomeâ€"Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2020, 26, 812-820.	3.2	23
29	Children with cancer in the time of COVIDâ€19: An 8â€week report from the six pediatric oncoâ€hematology centers in Lombardia, Italy. Pediatric Blood and Cancer, 2020, 67, e28410.	0.8	82
30	Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort. Blood, 2020, 136, 43-44.	0.6	0
31	Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study. Blood, 2020, 136, 24-25.	0.6	0
32	Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH). Blood, 2020, 136, 14-15.	0.6	0
33	Hermansky-Pudlak syndrome type II and lethal hemophagocytic lymphohistiocytosis: Case description and review of the literature. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2476-2478.e5.	2.0	15
34	Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10â€"14 years as compared with those aged 15â€"17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. European Journal of Cancer, 2019, 122, 61-71.	1.3	14
35	Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza. Open Forum Infectious Diseases, 2019, 6, ofz430.	0.4	3
36	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica, 2019, 104, 1812-1821.	1.7	32

#	Article	IF	Citations
37	Nationwide central diagnosis review for childhood solid tumors: From concept to realization of an Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) integrated project. Pediatric Blood and Cancer, 2019, 66, e27749.	0.8	1
38	Acute myeloid leukaemia niche regulates response to Lâ€asparaginase. British Journal of Haematology, 2019, 186, 420-430.	1.2	18
39	First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia. Journal of Clinical Pathology, 2019, 72, 558-561.	1.0	10
40	Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosomeâ€“positive chronic myeloid leukemia. Blood, 2019, 134, 2036-2045.	0.6	33
41	Human Fibrinogen Concentrate and Fresh Frozen Plasma in the Management of Severe Acquired Hypofibrinogenemia in Children With Acute Lymphoblastic Leukemia: Results of a Retrospective Survey. Journal of Pediatric Hematology/Oncology, 2019, 41, 275-279.	0.3	3
42	A phase 1/2, openâ€label, doseâ€escalation study of midostaurin in children with relapsed or refractory acute leukaemia. British Journal of Haematology, 2019, 185, 623-627.	1.2	23
43	ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. Haematologica, 2019, 104, 533-545.	1.7	21
44	Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol. Blood, 2019, 134, 2589-2589.	0.6	5
45	Combination Antifungal Therapy for Invasive Mold Infections Among Pediatric Patients with Hematological Malignancies: Data from A Real-Life Case-Series. Pathogens and Immunity, 2019, 4, 180.	1.4	3
46	Inotuzumab ozogamicin in older patients with acute lymphoblastic leukaemia: premises and promises. Lancet Oncology, The, 2018, 19, 159-160.	5.1	1
47	A threeâ€mi<scp>RNA</scp>â€based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) <scp>RUNX</scp>1â€<scp>RUNX</scp>1T1 acute myeloid leukaemia. British Journal of Haematology, 2018, 183, 298-301.	1.2	8
48	Therapeutic Drug Monitoring of Asparaginase Activityâ€”Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial. Therapeutic Drug Monitoring, 2018, 40, 93-102.	1.0	16
49	Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). Journal of Clinical Oncology, 2018, 36, 244-253.	0.8	71
50	Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP). Blood Cancer Journal, 2018, 8, 115.	2.8	6
51	A novel <scp>EP</scp>300 mutation associated with Rubinsteinâ€Taybi syndrome type 2 presenting as combined immunodeficiency. Pediatric Allergy and Immunology, 2018, 29, 776-781.	1.1	4
52	Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis. Blood, 2018, 132, LBA-6-LBA-6.	0.6	15
53	Prognostic significance of flowâ€cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the <scp>AIEOP</scp>â€<scp>AML</scp> 2002/01 study protocol. British Journal of Haematology, 2017, 177, 116-126.	1.2	54
54	Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations. Cancer Chemotherapy and Pharmacology, 2017, 79, 1267-1271.	1.1	5

#	Article	IF	Citations
55	Acute myeloid leukemia in Baraitserâ€“Winter cerebrofrontofacial syndrome. American Journal of Medical Genetics, Part A, 2017, 173, 546-549.	0.7	11
56	Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL. Blood, 2017, 130, 2146-2149.	0.6	7
57	A Case of Tâ€cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia. Pediatric Blood and Cancer, 2016, 63, 1660-1663.	0.8	10
58	Road Traffic Pollution and Childhood Leukemia: A Nationwide Case-control Study in Italy. Archives of Medical Research, 2016, 47, 694-705.	1.5	10
59	Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica, 2016, 101, 279-285.	1.7	164
60	Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 4381-4389.	0.8	478
61	Williams syndrome and mature B-Leukemia: A random association?. European Journal of Medical Genetics, 2016, 59, 634-640.	0.7	9
62	Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematology,the, 2016, 3, e80-e86.	2.2	95
63	Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing. Journal of Hematology and Oncology, 2015, 8, 69.	6.9	14
64	Outcome of children with acute myeloid leukaemia (<scp>AML</scp>) experiencing primary induction failure in the <scp>AIEOP AML</scp> 2002/01 clinical trial. British Journal of Haematology, 2015, 171, 566-573.	1.2	18
65	Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. Haematologica, 2015, 100, e99-e101.	1.7	35
66	Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leukemia and Lymphoma, 2015, 56, 2273-2280.	0.6	125
67	Still trying to pick the best asparaginase preparation. Lancet Oncology, The, 2015, 16, 1580-1581.	5.1	3
68	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 2949-2962.	0.8	277
69	A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114). Blood, 2015, 126, 2564-2564.	0.6	5
70	The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01. Haematologica, 2014, 99, 1472-1478.	1.7	42
71	SETIL: Italian multicentric epidemiological caseâ€“control study on risk factors for childhood leukaemia, non hodgkin lymphoma and neuroblastoma: study population and prevalence of risk factors in Italy. Italian Journal of Pediatrics, 2014, 40, 103.	1.0	9
72	Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. British Journal of Haematology, 2014, 166, 902-910.	1.2	22

#	Article	IF	Citations
73	Biological therapies in monogenic autoinflammatory diseases: long-term efficacy and safety. Italian Journal of Pediatrics, 2014, 40, .	1.0	0
74	Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in Non-Hodgkin Lymphoma. Journal of Hematology and Oncology, 2014, 7, 82.	6.9	12
75	Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment. Hematology Reports, 2014, 6, 5554.	0.3	14
76	Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood, 2014, 123, 1470-1478.	0.6	69
77	Shedding light on the asparaginase galaxy. Blood, 2014, 123, 1976-1978.	0.6	5
78	Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment. Blood, 2014, 124, 2292-2292.	0.6	17
79	Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3703-3703.	0.6	19
80	Outcome of Early T-Cell Precursor Acute Lymphoblastic Leukemia in AIEOP Patients Treated with the AIEOP-BFM ALL 2000 Study. Blood, 2014, 124, 3780-3780.	0.6	1
81	Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer. European Journal of Clinical Pharmacology, 2013, 69, 1739-1746.	0.8	35
82	Asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy. Pediatric Blood and Cancer, 2013, 60, 1915-1915.	0.8	5
83	Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia. Leukemia, 2013, 27, 2419-2421.	3.3	25
84	Cerebroretinal Microangiopathy With Calcifications and Cysts Associated With CTC1 and NDP Mutations. Journal of Child Neurology, 2013, 28, 1702-1708.	0.7	11
85	Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium. Journal of Clinical Oncology, 2013, 31, 2460-2468.	0.8	75
86	Screening for Coagulopathy and Identification of Children With Acute Lymphoblastic Leukemia at a Higher Risk of Symptomatic Venous Thrombosis. Journal of Pediatric Hematology/Oncology, 2013, 35, 348-355.	0.3	38
87	Optimizing asparaginase therapy for acute lymphoblastic leukemia. Current Opinion in Oncology, 2013, 25, S1-S9.	1.1	63
88	Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group. Journal of Clinical Oncology, 2013, 31, 599-607.	0.8	197
89	A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1. American Journal of Medical Genetics, Part A, 2013, 161, 1401-1404.	0.7	5
90	Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood, 2013, 122, 170-178.	0.6	162

#	Article	IF	Citations
91	A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2013, 122, 70-70.	0.6	20
92	DHH-RHEBL1fusion transcript: a novel recurrent feature in the new landscape of pediatricCBFA2T3-GLIS2-positive acute myeloid leukemia. Oncotarget, 2013, 4, 1712-1720.	0.8	23
93	Core Binding Factor Acute Myeloid Leukemia In Pediatric Patients Enrolled In The AIEOP AML 2002/01 Trial: The Impact Of Minimal Residual Disease On Patient Outcome. Blood, 2013, 122, 3884-3884.	0.6	14
94	Genetic Characterization Of Williams Beuren Syndrome Associated With Non-Hodgkin Lymphoma. Blood, 2013, 122, 4898-4898.	0.6	0
95	Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol. Blood, 2012, 120, 3586-3586.	0.6	2
96	Favourable Outcome in Infants with Acute Myeloid Leukemia Treated with the AIEOP AML 2002/01 Protocol. Blood, 2012, 120, 3585-3585.	0.6	0
97	Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.. Blood, 2012, 120, 2480-2480.	0.6	0
98	MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia, 2011, 25, 560-563.	3.3	31
99	Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease. Expert Review of Anticancer Therapy, 2011, 11, 1391-1401.	1.1	8
100	Hemophagocytic lymphohistiocytosis with neurological presentation: MRI findings and a nearly miss diagnosis. Neurological Sciences, 2011, 32, 473-477.	0.9	35
101	Lâ€asparaginase treatment in acute lymphoblastic leukemia. Cancer, 2011, 117, 238-249.	2.0	453
102	Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia, 2010, 24, 255-264.	3.3	148
103	GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials. Blood, 2010, 116, 871-871.	0.6	7
104	Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias. Cancer Chemotherapy and Pharmacology, 2009, 63, 563-566.	1.1	14
105	Tailoring treatment strategy for acute promyelocytic leukemia in lowâ€income countries. Pediatric Blood and Cancer, 2009, 53, 303-305.	0.8	4
106	Clofarabine, cyclophosphamide and etoposide as singleâ€course reâ€induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. British Journal of Haematology, 2009, 147, 371-378.	1.2	88
107	Adrenal axis function after highâ€dose steroid therapy for childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2008, 50, 537-541.	0.8	77
108	Minimal residual disease is an important predictive factor of outcome in children with relapsed â€˜high-riskâ€™ acute lymphoblastic leukemia. Leukemia, 2008, 22, 2193-2200.	3.3	81

#	Article	IF	Citations
109	Long-Term Results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: Insight on the Prognostic Value of DNA Index in the Framework of Berlin-Frankfurt-Muensterâ€“Based Chemotherapy. Journal of Clinical Oncology, 2008, 26, 283-289.	0.8	69
110	Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Interim Results of the CA180-018 Phase I Study from the ITCC Consortium.. Blood, 2008, 112, 3241-3241.	0.6	9
111	Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood, 2007, 109, 4151-4157.	0.6	190
112	Are genotypes of glutathione S-transferase superfamily a risk factor for childhood acute lymphoblastic leukemia? Results of an Italian caseâ€“control study. Leukemia, 2007, 21, 1122-1124.	3.3	8
113	A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica, 2006, 91, 24-31.	1.7	66
114	Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies. Haematologica, 2006, 91, 534-7.	1.7	27
115	Ischemic Stroke in Children Treated for Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2005, 27, 153-157.	0.3	44
116	Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia, 2005, 19, 2043-2053.	3.3	80
117	Long-Term Results of a Randomized Trial on Extended Use of High Dose l-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2005, 23, 7161-7167.	0.8	180
118	Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study. Haematologica, 2005, 90, 1186-91.	1.7	15
119	Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia. Leukemia, 2004, 18, 1441-1444.	3.3	23
120	Clinical features of childhood acute myeloid leukaemia with specific gene rearrangements. Leukemia, 2004, 18, 1427-1429.	3.3	7
121	Outcome of very late relapse in children with acute lymphoblastic leukemia. Haematologica, 2004, 89, 427-34.	1.7	30
122	FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. British Journal of Haematology, 2003, 120, 89-92.	1.2	56
123	Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia. Leukemia, 2003, 17, 981-983.	3.3	12
124	T-immunophenotype is associated with an increased prevalence of thrombosis in children with acute lymphoblastic leukemia. A retrospective study. Haematologica, 2003, 88, 1079-80.	1.7	13
125	Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood, 2002, 100, 420-426.	0.6	92
126	Effect of Protracted High-Dose l-Asparaginase Given as a Second Exposure in a Berlin-Frankfurt-MÃ¼nsterâ€“Based Treatment: Results of the Randomized 9102 Intermediate-Risk Childhood Acute Lymphoblastic Leukemia Studyâ€”A Report From the Associazione Italiana Ematologia Oncologia Pediatrica. Journal of Clinical Oncology, 2001, 19, 1297-1303.	0.8	54

#	Article	IF	Citations
127	Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Acute Lymphoblastic Leukemia Studies, 1982â€“1995. Leukemia, 2000, 14, 2196-2204.	3.3	92
128	L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Annals of Oncology, 2000, 11, 189-193.	0.6	90
129	Bone marrow biopsy as prognostic indicator in childhood acute lymphoblastic leukemiaâ€"another opinion. , 1998, 30, 315-316a.		0
130	MTHFR 677Câ†'T mutation and neural-tube defects. Lancet, The, 1997, 350, 1479-1480.	6.3	4
131	Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-MÃ¼nster groups.. Journal of Clinical Oncology, 1997, 15, 2786-2791.	0.8	76
132	L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Annals of Oncology, 1996, 7, 725-730.	0.6	34
133	Myelodysplastic Syndrome in a Child With Rothmund-Thomson Syndrome. Journal of Pediatric Hematology/Oncology, 1996, 18, 96.	0.3	26
134	Rothmund-Thomson Syndrome, Malignant Diseases, and Treatment Opportunities. Pediatric Hematology and Oncology, 1996, 13, 195-196.	0.3	4
135	Prognostic Value of Nephromegaly at Diagnosis of Childhood Acute Lymphoblastic Leukemia. Acta Haematologica, 1995, 94, 84-85.	0.7	23
136	Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer, 1995, 75, 1684-1693.	2.0	90
137	Letter to the editor: â€œchildhood ALL and cystic fibrosisâ€"treatment and outcomeâ€. Medical and Pediatric Oncology, 1995, 25, 223-223.	1.0	1
138	Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-MÃ¼nster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.. Journal of Clinical Oncology, 1995, 13, 2497-2502.	0.8	91
139	Efficacy of Prolonged Low-Dose Steroid Treatment in a Child with Idiopathic Hypereosinophilic Syndrome: A Case Report. Pediatric Hematology and Oncology, 1995, 12, 209-212.	0.3	10
140	Central Venous Catheter Clots: Incidence, Clinical Significance and Catheter Care in Patients with Hematologic Malignancies. Pediatric Hematology and Oncology, 1995, 12, 243-250.	0.3	42
141	Severe Osteoporosis and Multiple Vertebral Collapses in a Child during Treatment for B-ALL. Acta Haematologica, 1993, 89, 38-42.	0.7	19
142	Central Venous Catheter-Related Infections in Pediatric Hematology-Oncology Patients: Role of Home and Hospital Management. Pediatric Hematology and Oncology, 1992, 9, 115-123.	0.3	25
143	Lineage Switch in a Childhood T-Cell Acute Lymphoblastic Leukemia. Pediatric Hematology and Oncology, 1992, 9, 281-288.	0.3	3
144	Microgranular variant of acute promyelocytic leukemia in children.. Journal of Clinical Oncology, 1992, 10, 1413-1418.	0.8	81

#	Article	IF	Citations
145	Isolated Muscular Relapse in a Child with B-Acute Lymphoblastic Leukemia, Off Therapy. Pediatric Hematology and Oncology, 1991, 8, 263-267.	0.3	0
146	Convulsions and Intracranial Calcifications in a Leukemic Infant Receiving Only Intrathecal Methotrexate as Central Nervous System Prophylaxis. Pediatric Hematology and Oncology, 1987, 4, 269-272.	0.3	0
147	Abnormal visual-evoked potentials in leukemic children after cranial radiation. Medical and Pediatric Oncology, 1985, 13, 313-317.	1.0	17
148	Lessons After the Early Management of the COVID-19 Outbreak in a Pediatric Transplant and Hemato-Oncology Center Embedded within a COVID-19 Dedicated Hospital in Lombardia, Italy. <i>Estote Parati.</i> (Be Ready.). SSRN Electronic Journal, 0, , .	0.4	8